This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
6vja
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Structure of CD20 in complex with rituximab Fab== | |
| - | + | <StructureSection load='6vja' size='340' side='right'caption='[[6vja]], [[Resolution|resolution]] 3.30Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[6vja]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6VJA OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6VJA FirstGlance]. <br> | |
| - | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=Y01:CHOLESTEROL+HEMISUCCINATE'>Y01</scene></td></tr> | |
| - | [[Category: | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6vja FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6vja OCA], [http://pdbe.org/6vja PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6vja RCSB], [http://www.ebi.ac.uk/pdbsum/6vja PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6vja ProSAT]</span></td></tr> |
| + | </table> | ||
| + | == Disease == | ||
| + | [[http://www.uniprot.org/uniprot/CD20_HUMAN CD20_HUMAN]] Defects in MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5) [MIM:[http://omim.org/entry/613495 613495]]; also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range, but can be low.<ref>PMID:20038800</ref> | ||
| + | == Function == | ||
| + | [[http://www.uniprot.org/uniprot/CD20_HUMAN CD20_HUMAN]] This protein may be involved in the regulation of B-cell activation and proliferation. | ||
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Croll, T I]] | ||
| + | [[Category: Rohou, A]] | ||
| + | [[Category: Antibody]] | ||
| + | [[Category: Cd20]] | ||
| + | [[Category: Human]] | ||
| + | [[Category: Immune system]] | ||
| + | [[Category: Ms4a1]] | ||
| + | [[Category: Rituximab]] | ||
| + | [[Category: Therapeutic]] | ||
Revision as of 09:28, 26 February 2020
Structure of CD20 in complex with rituximab Fab
| |||||||||||
Categories: Large Structures | Croll, T I | Rohou, A | Antibody | Cd20 | Human | Immune system | Ms4a1 | Rituximab | Therapeutic
